Arrowhead Pharmaceuticals is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.